References
- Adler M, Unger M, Lee G. (2000). Surface composition of spray-dried particles of bovine serum albumin/trehalose/surfactant. Pharm Res 17:863–70
- Agu RU, Ugwoke MI, Armand M, et al. (2001). The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2:198–209
- Andrade F, Videira M, Ferreira D, et al. (2011). Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine (Lond) 6:123–41
- Elversson J, Millqvist-Fureby A. (2006). In situ coating–an approach for particle modification and encapsulation of proteins during spray-drying. Int J Pharm 323:52–63
- Gao J, Ding X, Chu C, et al. (2009). Dry powder inhalations containing thymopentin and its immunomodulating effects in Wistar rats. Eur J Pharm Sci 36:572–9
- Jin X, Huang A, Ping Q, et al. (2011). Box-Behnken optimization design and enhanced oral bioavailability of thymopentin-loaded poly (butyl cyanoacrylate) nanoparticles. Pharmazie 66:339–47
- Learoyd TP, Burrows JL, French E, et al. (2008). Chitosan-based spray-dried respirable powders for sustained delivery of terbutaline sulfate. Eur J Pharm Biopharm 68:224–34
- Li HY, Seville PC, Williamson IJ, et al. (2005). The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J Gene Med 7:343–53
- Li YZ, Sun X, Gong T, et al. (2010). Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm Res 27:1977–86
- Padhi BK, Chougule MB, Misra A. (2006). Optimization of formulation components and characterization of large respirable powders containing high therapeutic payload. Pharm Dev Technol 11:465–75
- Panchal R, Patel H, Patel V, et al. (2012). Formulation and evalution of montelukast sodium – chitosan based spray dried microspheres for pulmonary drug delivery. J Pharm Bioallied Sci 4:S110–11
- Rabbani NR, Seville PC. (2005). The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Release 110:130–40
- Seville PC, Li HY, Learoyd TP. (2007a). Spray-dried powders for pulmonary drug delivery. Crit Rev Ther Drug Carrier Syst 24:307–60
- Seville PC, Learoyd TP, Li HY, et al. (2007b). Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol 178:40–50
- Shoyele SA, Slowey A. (2006). Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int J Pharm 314:1–8
- Stark B, Andreae F, Mosgoeller W, et al. (2008). Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation. Eur J Pharm Biopharm 70:153–64
- Wang J, Lu WL, Liang GW, et al. (2006). Pharmacokinetics, toxicity of nasal cilia and immunomodulating effects in Sprague–Dawley rats following intranasal delivery of thymopentin with or without absorption enhancers. Peptides 27:826–35
- Wang L, Zhang Y, Tang X. (2009). Characterization of a new inhalable thymopentin formulation. Int J Pharm 375:1–7
- Yamamoto H, Kuno Y, Sugimoto S, et al. (2005). Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 102:373–81
- Yang M, Yamamoto H, Kurashima H, et al. (2012). Design and evaluation of poly(dl-lactic-co-glycolic acid) nanocomposite particles containing salmon calcitonin for inhalation. Eur J Pharm Sci 46:374–80
- Yang M, Velaga S, Yamamoto H, et al. (2007). Characterisation of salmon calcitonin in spray-dried powder for inhalation. Effect of chitosan. Int J Pharm 331:176–81